NPM1 and acute myeloid leukemia: Mutant NPM1, a commonly mutated protein in adult AML, requires cytoplasmic localization for its leukemogenic activity, which is inhibited by treatment with SINE compounds such as selinexor or its more potent second-generation relative, eltanexor [186].